Unity Biotechnology has been granted a patent for a method to treat retinal vasculopathies like diabetic macular edema and age-related macular degeneration. The method involves administering a therapeutically effective dose of a compound to the patient. GlobalData’s report on Unity Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Unity Biotechnology Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Unity Biotechnology, Cancer treatment biomarkers was a key innovation area identified from patents. Unity Biotechnology's grant share as of April 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Treating retinal vasculopathies with compound-meglumine

Source: United States Patent and Trademark Office (USPTO). Credit: Unity Biotechnology Inc

A recently granted patent (Publication Number: US11951115B2) discloses a method for treating patients suffering from retinal vasculopathy, specifically diabetic macular edema (DME) or diabetic retinopathy (DR). The method involves administering a therapeutically effective dose of a meglumine salt of a compound of Formula I to the patient. The treatment is targeted at patients with specific baseline characteristics, including best corrected visual acuity (BCVA), previous anti-vascular endothelial growth factor (anti-VEGF) treatment, central subfield thickness (CST), hemoglobin A1C (HbA1C) levels, and intraocular pressure (IOP).

Furthermore, the patent outlines various dosing regimens for the administration of the Compound-meglumine, including loading doses and maintenance doses, to achieve desired outcomes such as CST reduction, absence of macular fluid and exudation, improvement in BCVA, reduction in ocular avascular area, regression in neovascularization, and improvement in diabetic retinopathy severity scale (DRSS). The method also specifies the frequency of administration, ranging from every 2 months to every 12 months, based on the patient's response to treatment. Overall, the patent provides a detailed protocol for the effective treatment of retinal vasculopathy, offering a comprehensive approach to managing these conditions in patients with specific baseline characteristics and treatment history.

To know more about GlobalData’s detailed insights on Unity Biotechnology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies